Bing

SEARCH HISTORY

Research analysts at Roth Capital set a $2.50 price objective on shares of Alexza Pharmaceuticals (NASDAQ:ALXA) stock in a report released on Friday. The firm currently has a a “hold” rating on the stock. Roth Capital’s target price would indicate a ...
wkrb13.com · 3/27/2015
Alexza Pharmaceuticals (NASDAQ:ALXA) was upgraded by Zacks from a “sell” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $1.25 price target on the stock. Zacks‘s price target indicates a potential ...
Mideast Times · 5/28/2015
Alexza Pharmaceuticals (NASDAQ:ALXA) was upgraded by Zacks from a “sell” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $1.25 price target on the stock. Zacks‘s price target indicates a potential ...
Ticker Report · 5/27/2015
More from Bing News
On July 26, 2013, Pres & CEO of Alexza Pharmaceuticals Inc. (ALXA) Thomas Braxton King bought 40,000 shares of ALXA stock at an average price of $4.48. The total transaction amount was $179,200 Thomas B. King has been the President, CEO and …
Guru Focus · 7/29/2013
it goes without saying that the FDA approvals for AEZS and KERX are gong to be HUGE positives by any yardstick. Alexza Pharmaceuticals Inc (NASDAQ: ALXA) is another pharmaceutical company which registered a 17 per cent surge in stock price last …
Smallcap Network · ByBrian Prescott · 3/5/2012
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced a 10-for-1 reverse split of its common stock. The reverse stock split became effective today at 5:01 p.m. Eastern Time and Alexza's common stock will begin trading on The NASDAQ Global Market …
StreetInsider · 6/12/2012
Foundation Medicine Inc (FMI) traded at $48.82 + 24.89 (104.01 percent) on 8,184,382 total share volume. The company is +119.71 percent year-to-date, and +93.14 percent over the last 12 months. Tekmira Pharmaceuticals Corp (TKMR) traded at $24.51 + …
Fx Pips · 1/13/2015
ALEXZA PHARMACEUTICALS INC (ALXA): Free Stock Analysis Report ALLOT COMMUNICATIONS LTD ORD (ALLT): Free Stock Analysis Report (A^MID): Free Stock Analysis Report AMR CORP (AAMRQ): Free Stock Analysis Report ANN INC (ANN) …
Yahoo Finance · 7/18/2012
Roth Capital set a $2.50 price objective on Alexza Pharmaceuticals (NASDAQ:ALXA) in a report released on Friday. The firm currently has a a hold rating on the stock. Shares of Alexza Pharmaceuticals (NASDAQ:ALXA) traded down 0.99% during mid-day …
sleekmoney.com · 3/27/2015
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares are climbed 1.25% to $4.09 the U.S. Food and Drug Administration approves the company’s to start Phase II trial for its rheumatoid arthritis treatment. Subscribe to daily free stock
TransWorldNews · 8/26/2010